Full-Time

Domain Architect

Sites & Services

Updated on 8/1/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

In Person

Category
Architecture & Civil Engineering (2)
,

Get referred to Roche

See people who can refer or advise you

Requirements
  • A Bachelor's or Master's degree in IT, Computer Science, Architecture, or a related technical discipline.
  • A proven track record as a senior Domain or Enterprise Architect in a complex, matrixed, or federated environment.
  • Comprehensive experience supporting corporate real estate, facility management, physical security, or building management systems.
  • Proficiency in technical architecture design, including capability modeling, target-state blueprints, and aligning roadmaps with evolving business capabilities.
  • Technical fluency across IoT ecosystems, smart building platforms, cloud architectures, and connected workplace applications.
  • The ability to influence, align, and inspire federated teams of architects without direct reporting authority.
  • Expertise in architectural storytelling, translating complex technical concepts into business narratives, and building trust with senior leadership.
Responsibilities
  • Drive strategic business partnering as the primary architectural liaison between SPG and the Sites function to align real estate priorities with multi-year technology roadmaps.
  • Orchestrate the global architecture network across regional sites, empowering embedded domain and solution architects to execute efficiently while adhering to shared enterprise principles.
  • Lead architecture governance by defining technology guardrails and non-functional requirements, including IoT network security, physical access control resilience, and operational data privacy.
  • Steer critical program delivery for smart building deployments, connected workplace technologies, and global real estate portfolio rationalization.
  • Develop Facility Management capability maps, target-state architectures, and reference blueprints using the ArchiMEDES toolchain.
  • Align portfolio investments by embedding architectural insights into funding decisions, maximizing platform reuse, and minimizing technical debt across global sites.
  • Evaluate emerging technology innovations and vendor solutions, such as digital twins for buildings and advanced IoT facility ecosystems, for alignment with operational needs.
  • Foster a collaborative workplace culture that balances enterprise coherence with local agility and transforms complex architectural visions into scalable value.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • cobas BV/CV clearance expands Roche’s molecular diagnostics menu in women’s health.
  • Susvimo’s European progress strengthens a differentiated continuous-delivery ophthalmology franchise.
  • Roche’s global scale across 100-plus countries supports commercialization and pipeline deployment.

What critics are saying

  • Susvimo still needs European Commission approval before Roche can monetize the label.
  • Diagnostics products face slow lab adoption and pricing pressure after technical clearance.
  • Patent expirations or biosimilar competition can rapidly erode blockbuster pharmaceutical revenue.

What makes Roche unique

  • Founded in Basel in 1896, Roche built quality-focused pharmaceuticals from the start.
  • Genentech acquisition in 2009 made Roche the world’s largest biotechnology company.
  • Roche leads in in-vitro diagnostics alongside medicines, enabling integrated care platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.